A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

July 31, 2019

Conditions
Acute Respiratory Distress Syndrome
Interventions
BIOLOGICAL

MultiStem

BIOLOGICAL

MultiStem

BIOLOGICAL

Placebo

Trial Locations (10)

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

44106

University Hospitals - Cleveland Medical Center, Cleveland

B15 2TH

Queen Elizabeth Hospital, Birmingham

CB2 0QQ

Addenbrooke's Hospital, Cambridge

NW12BU

University College London Hospital, London

SW17 0QT

St. Georges Hospital, London

M139WL

Manchester Royal Infirmary, Manchester

M239LT

Wythenshawe Hospital, Manchester

OX3 9DU

John Radcliffe Hospital, Oxford

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Athersys Limited

INDUSTRY

collaborator

Cell Therapy Catapult

OTHER

lead

Healios K.K.

INDUSTRY

NCT02611609 - A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter